Novo Nordisk AS (NVO)
105.06
+2.43
(+2.37%)
USD |
NYSE |
Nov 22, 16:00
105.08
+0.02
(+0.02%)
Pre-Market: 20:00
Novo Nordisk Cash from Financing (Quarterly): -2.741B for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -2.741B |
| June 30, 2024 | 2.443B |
| March 31, 2024 | -3.843B |
| December 31, 2023 | -1.424B |
| September 30, 2023 | -2.892B |
| June 30, 2023 | -1.880B |
| March 31, 2023 | -2.974B |
| December 31, 2022 | -1.368B |
| September 30, 2022 | -1.742B |
| June 30, 2022 | -1.346B |
| March 31, 2022 | -2.887B |
| December 31, 2021 | 706.40M |
| September 30, 2021 | -1.795B |
| June 30, 2021 | -621.02M |
| March 31, 2021 | -2.347B |
| December 31, 2020 | 68.32M |
| September 30, 2020 | -1.879B |
| June 30, 2020 | -1.135B |
| March 31, 2020 | -1.994B |
| December 31, 2019 | -809.38M |
| September 30, 2019 | -1.462B |
| June 30, 2019 | -991.30M |
| March 31, 2019 | -2.058B |
| December 31, 2018 | -732.56M |
| September 30, 2018 | -1.602B |
| Date | Value |
|---|---|
| June 30, 2018 | -801.92M |
| March 31, 2018 | -2.332B |
| December 31, 2017 | -519.59M |
| September 30, 2017 | -2.036B |
| June 30, 2017 | -910.12M |
| March 31, 2017 | -1.966B |
| December 31, 2016 | -563.10M |
| September 30, 2016 | -1.635B |
| June 30, 2016 | -1.043B |
| March 31, 2016 | -2.539B |
| December 31, 2015 | -657.78M |
| September 30, 2015 | -760.74M |
| June 30, 2015 | -884.11M |
| March 31, 2015 | -2.176B |
| December 31, 2014 | -702.88M |
| September 30, 2014 | -591.83M |
| June 30, 2014 | -1.019B |
| March 31, 2014 | -2.419B |
| December 31, 2013 | -544.69M |
| September 30, 2013 | -548.45M |
| June 30, 2013 | -1.194B |
| March 31, 2013 | -1.922B |
| December 31, 2012 | -383.65M |
| September 30, 2012 | -253.72M |
| June 30, 2012 | -1.211B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.843B
Minimum
Mar 2024
2.443B
Maximum
Jun 2024
-1.523B
Average
-1.769B
Median
Cash from Financing (Quarterly) Benchmarks
| Ascendis Pharma AS | -- |
| Amgen Inc | -3.651B |
| AstraZeneca PLC | -4.131B |
| Viking Therapeutics Inc | 2.522M |
| Evaxion Biotech AS | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 6.658B |
| Cash from Investing (Quarterly) | -3.131B |
| Free Cash Flow | 9.828B |
| Free Cash Flow Per Share (Quarterly) | 1.064 |
| Free Cash Flow to Equity (Quarterly) | 4.406B |
| Free Cash Flow to Firm (Quarterly) | 4.748B |
| Free Cash Flow Yield | 2.09% |